MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent & Trademark Office for Synthetic Cannabinoid C...
April 22 2021 - 9:20AM
Business Wire
- Patent protects Supera-CBD, a preclinical cannabidiol
derivative that targets cannabinoid receptor type 2 for the
treatment of neuroinflammatory and neurodegenerative diseases.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage
pharmaceutical company committed to extending healthy lifespan by
focusing on developing two therapeutic platforms, announced today
that the United States Patent and Trademark Office (USPTO) issued a
Notice of Allowance for application no. 16/612,472, entitled
“Synthetic Cannabinoid Compounds for the Treatment of Substance
Addiction and Other Disorders.”
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210422005689/en/
Supera-CBD is well positioned to address
key unmet needs in epilepsy and chronic pain (Graphic: Business
Wire)
The allowed claims cover the new molecular entity Supera-CBD as
well as pharmaceutical compositions containing the compound. The
USPTO found the claims patentable based in part on the compound’s
unexpectedly improved activity and selectivity toward inhibiting
cannabinoid receptor type 2 (CB2), a key therapeutic target for
neuroinflammatory and neurodegenerative diseases.
“The issuance of this Notice of Allowance for our molecule,
Supera-CBD, continues to demonstrate our steadfast commitment to
moving forward with and protecting our entire product portfolio,"
said Adam Kaplin, M.D., Chief Scientific Officer of MyMD. “We are
thrilled that Supera-CBD has shown strong promise in treating
neuroinflammatory and neurodegenerative diseases, and is expected
to be a major focus for our company as we move forward.”
Supera-CBD is a non-toxic, synthetic, preclinical cannabidiol
derivative that has been shown in in vitro studies to be
approximately 7-8x more effective than plant-derived CBD in
inhibiting MAO-A and MAO-B and more than 3x more effective than
plant-derived CBD in inhibiting CB2, which should enhance its
therapeutic potential to treat pain, inflammation, and
neurodegeneration.
Supera-CBD is being developed to address anxiety, chronic pain,
and seizures and is on an expected path toward human clinical
trials as a proposed therapy for epilepsy, followed by chronic
pain.
MyMD has continued to elevate its work in inflammatory diseases
and was previously issued US Patent Number 10,835,523 B2, titled
“Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for
Treating Cancers, Autoimmune Disorders, and Other Disorders
Associated with Chronic Inflammation,” which was a significant
milestone in the company’s approach toward anti-aging product
therapies.
The grant of the ‘472 application will add to the company’s
growing worldwide patent portfolio, which includes eleven granted
patents pertaining to its lead compound, MYMD-1. These patents,
coupled with clinical studies underway, have laid the foundation
for the planned Phase 2 trial investigating the use of MYMD-1 in
patients with depression due to COVID-19, which was recently
announced.
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms. MYMD-1 is a drug platform based on a
clinical stage small molecule that regulates the immunometabolic
system to control TNF-α and other pro-inflammatory cytokines.
MYMD-1 is being developed to treat autoimmune diseases, including
those currently treated with non-selective TNF-α blocking drugs,
and aging and longevity. Supera-CBD is a drug platform based on a
novel (patent pending) synthetic derivative of cannabidiol (CBD)
that targets numerous key receptors including CB2 and opioid
receptors and inhibits monoamine oxidase. Supera-CBD is being
developed to address the rapidly growing CBD market, that includes
FDA approved drugs and CBD products not currently regulated as a
drug. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates, the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates, the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the registration statement on Form S-4 filed
by MyMD on January 15, 2021, as amended. Forward-looking statements
speak only as of the date they are made and MyMD disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210422005689/en/
Investor Contact: Brett Mass 646-536-7331
brett@haydenir.com www.haydenir.com
Media Contact: Will Johnson 201-465-8019
MYMD@antennagroup.com www.antennagroup.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024